Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All antiandrogen studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAntiandrogenAntiandrogens (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 93% Improvement Relative Risk Death/intubation 81% Canrenone for COVID-19  Vicenzi et al.  LATE TREATMENT Is late treatment with antiandrogens beneficial for COVID-19? Retrospective 69 patients in Italy Study compares with RAAS inhibitors or vasodilator agents Lower mortality (p<0.0001) and death/intubation (p=0.002) c19early.org Vicenzi et al., J. Clinical Medicine, Sep 2020 Favors canrenone Favors RAAS inhibit..

The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients

Vicenzi et al., Journal of Clinical Medicine, doi:10.3390/jcm9092943
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
5th treatment shown to reduce risk in August 2020
 
*, now known with p = 0.000000056 from 49 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Retrospective 69 consecutive hospitalized COVID-19 patients in Italy, 30 patients receiving canrenone, and 39 treated with vasodilator agents or renin–angiotensin–aldosterone system (RAAS) inhibitors, showing lower mortality with canrenone.
risk of death, 93.0% lower, HR 0.07, p < 0.001, treatment 30, control 39, adjusted per study, model 2, multivariable.
risk of death/intubation, 81.0% lower, HR 0.19, p = 0.002, treatment 30, control 39, adjusted per study, model 2, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Vicenzi et al., 11 Sep 2020, retrospective, Italy, peer-reviewed, 10 authors, this trial compares with another treatment - results may be better when compared to placebo. Contact: marco.vicenzi@unimi.it (corresponding author), massimiliano.ruscica@unimi.it (corresponding author), irene.rota85@gmail.com, angelo.ratti.91@gmail.com, dicosola.roberta@gmail.com, alberto.corsini@unimi.it, simona.iodice@unimi.it, valentina.bollati@unimi.it, stefano.aliberti@unimi.it, francesco.blasi@unimi.it.
This PaperAntiandrogensAll
The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
Marco Vicenzi, Massimiliano Ruscica, Simona Iodice, Irene Rota, Angelo Ratti, Roberta Di Cosola, Alberto Corsini, Valentina Bollati, Stefano Aliberti, Francesco Blasi
Journal of Clinical Medicine, doi:10.3390/jcm9092943
Background: In COVID-19 patients, aldosterone via angiotensin-converting enzyme-2 deregulation may be responsible for systemic and pulmonary vasoconstriction, inflammation, and oxidative organ damage. Aim: To verify retrospectively the impact of the mineralcorticoid receptor antagonist canrenone i.v. on the need of invasive ventilatory support and/or all-cause in-hospital mortality. Methods: Sixty-nine consecutive COVID-19 patients, hospitalized for moderate to severe respiratory failure at Fondazione Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico of Milan, received two different therapeutic approaches in usual care according to the personal skills and pharmacological management experience of the referral medical team. Group A (n = 39) were given vasodilator agents or renin-angiotensin-aldosterone system (RAAS) inhibitors and group B (n = 30) were given canrenone i.v. Results: Among the 69 consecutive COVID-19 patients, those not receiving canrenone i.v. (group A) had an event-free rate of 51% and a survival rate of 64%. Group B (given a mean dose of 200 mg/q.d. of canrenone for at least two days of continuous administration) showed an event-free rate of 80% with a survival rate of 87%. Kaplan-Meier analysis for composite outcomes and mortality showed log rank statistics of 0.0004 and 0.0052, respectively. Conclusions: The novelty of our observation relies on the independent positive impact of canrenone on the all-cause mortality and clinical improvement of COVID-19 patients ranging from moderate to severe diseases.
Author Contributions: Conceptualization, M.V., M.R., S.A., and F.B.; formal analysis, S.I.; investigation, I.R., R.D.C., and A.R.; resourcesa dn writing-original draft preparation, M.V., M.R., A.C., and V.B.; writing-review and editing, M.V., M.R., A.C., V.B., S.A., and F.B. All authors have read and agreed to the published version of the manuscript.
References
Ackermann, Verleden, Kuehnel, Haverich, Welte et al., Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19, N. Engl. J. Med, doi:10.1056/NEJMoa2015432
Alkhouli, Nanjundappa, Annie, Bates, Bhatt, Sex Differences in Case Fatality Rate of COVID-19: Insights From a Multinational Registry, Mayo. Clin. Proc, doi:10.1016/j.mayocp.2020.05.014
Armanini, Sabbadin, Dona, Clari, Bordin, Aldosterone receptor blockers spironolactone and canrenone: Two multivalent drugs, Expert Opin. Pharmacother, doi:10.1517/14656566.2014.896901
Batterink, Stabler, Tejani, Fowkes, Spironolactone for hypertension, Cochrane Database Syst. Rev, doi:10.1002/14651858.CD008169.pub2
Bonetti, Lerman, Lerman, Endothelial dysfunction: A marker of atherosclerotic risk, Arter. Thromb. Vasc. Biol, doi:10.1161/01.ATV.0000051384.43104.FC
Cadegiani, Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?, Am. J. Physiol. Endocrinol. Metab, doi:10.1152/ajpendo.00136.2020
Cadegiani, Goren, Wambier, Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS), Med Hypotheses, doi:10.1016/j.mehy.2020.110112
Cadegiani, Wambier, Goren, Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19, Front. Med, doi:10.3389/fmed.2020.00453
Cannata, Chiarito, Reimers, Azzolini, Ferrante et al., Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: Effects on blood pressure control and mortality, Eur. Heart J. Cardiovasc. Pharmacother
Chen, Tsai, Pan, Chou, Liao et al., Endothelial Dysfunction in Primary Aldosteronism, Int. J. Mol. Sci, doi:10.3390/ijms20205214
Dabrowski, Syska, Maczynska, Farkowski, Sawicki et al., Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation-A protocol of a pilot, randomized, double-blind, placebo-controlled study (CANREN-AF trial), Trials, doi:10.1186/s13063-020-04277-3
Epelman, Tang, Chen, Van Lente, Francis et al., Detection of soluble angiotensin-converting enzyme 2 in heart failure: Insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system, J. Am. Coll. Cardiol, doi:10.1016/j.jacc.2008.02.088
Figliozzi, Masci, Ahmadi, Tondi, Koutli et al., Predictors of Adverse Prognosis in Covid-19: A Systematic Review and Meta-analysis, Eur. J. Clin. Investig, doi:10.1111/eci.13362
Goren, Vano-Galvan, Wambier, Mccoy, Gomez-Zubiaur et al., A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain-A potential clue to the role of androgens in COVID-19 severity, J. Cosmet. Dermatol, doi:10.1111/jocd.13443
Hoffmann, Kleine-Weber, Schroeder, Kruger, Herrler et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Ma, Kam, Yan, Lam, Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: Current status, Br. J. Pharmacol, doi:10.1111/j.1476-5381.2010.00750.x
Mackey, King, Gurley, Kiefer, Liederbauer et al., Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults, Ann. Intern. Med, doi:10.7326/M20-1515
Mancia, Rea, Ludergnani, Apolone, Corrao, Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19, N. Engl. J. Med, doi:10.1056/NEJMoa2006923
Mantero, Lucarelli, Aldosterone antagonists in hypertension and heart failure, Ann. Endocrinol
Marini, Gattinoni, Management of COVID-19 Respiratory Distress, JAMA, doi:10.1001/jama.2020.6825
Mcgonagle, Sharif, O'regan, Bridgewood, The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease, Autoimmun. Rev, doi:10.1016/j.autrev.2020.102537
Nielsen, Treatment of female acne vulgaris with a cream containing the antiandrogen canrenone, Dermatologica, doi:10.1159/000249886
Patel, Rauf, Khan, Abu-Izneid, Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies, Biomed. Pharmacother, doi:10.1016/j.biopha.2017.07.091
Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area, JAMA
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review, JAMA, doi:10.1001/jama.2020.6019
Sarzani, Giulietti, Pentima, Giordano, Spannella, Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers, Eur. J. Prev. Cardiol, doi:10.1177/2047487320918421
Sobbrio, Granata, Panacea, Trimarchi, Effectiveness of short term canrenone treatment in idiopathic hirsutism, Minerva Endocrinol
Tan, Liao, Zhou, Mei, Wong, Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases, Curr. Opin. Pharmacol, doi:10.1016/j.coph.2017.12.002
Vicenzi, Di Cosola, Ruscica, Ratti, Rota et al., The liaison between respiratory failure and high blood pressure: Evidence from COVID-19 patients, Eur. Respir. J, doi:10.1183/13993003.01157-2020
Villard, Morquin, Molinari, Raingeard, Nagot et al., The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study, J. Clin. Med, doi:10.3390/jcm9072315
Wambier, Goren, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated, J. Am. Acad. Dermatol, doi:10.1016/j.jaad.2020.04.032
Who, Coronavirus Disease (COVID-19
Zhang, Zhu, Cai, Lei, Qin et al., Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19, Circ. Res
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit